Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aslan Pharmaceuticals Ltd ASLN

Healthcare Biotechnology
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness... see more

Recent & Breaking News (NDAQ:ASLN)

ASLAN Pharmaceuticals Appoints Dr Neil Graham as Independent Director

GlobeNewswire February 18, 2021

New Research Published in Toxicology in Vitro Provides Insight Into the Hepatotoxicity of DHODH Inhibitors Suggesting ASLAN003 Has the Potential to Be Best-In-Class

GlobeNewswire January 26, 2021

ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial

GlobeNewswire January 11, 2021

ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference

GlobeNewswire November 19, 2020

ASLAN Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2020

ASLAN Pharmaceuticals Initiates Third Dose Cohort of ASLAN004 in Atopic Dermatitis Clinical Trial

GlobeNewswire October 22, 2020

ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions

GlobeNewswire October 16, 2020

ASLAN Pharmaceuticals Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study

GlobeNewswire September 21, 2020

ASLAN Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference

GlobeNewswire September 10, 2020

ASLAN Pharmaceuticals Resumes Recruitment of New Patients Into ASLAN004 Study

GlobeNewswire August 24, 2020

ASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference 2020

GlobeNewswire August 7, 2020

ASLAN Pharmaceuticals Appoints Kenneth Kobayashi, MD, as Chief Medical Officer

GlobeNewswire August 3, 2020

ASLAN Pharmaceuticals Announces the Move of its Primary Listing to Nasdaq and Delisting From Taipei Exchange

GlobeNewswire July 17, 2020

ASLAN Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire July 13, 2020

ASLAN Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire May 11, 2020

UPDATE - ASLAN Pharmaceuticals Temporarily Pauses Recruitment of New Patients Into ASLAN004 Study Due to COVID-19

GlobeNewswire April 13, 2020

ASLAN Intends to Resume Screening as Soon as Government Restrictions are Lifted and is Taking Steps to Open Sites in Australia to Accelerate Recruitment

GlobeNewswire April 13, 2020

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

GlobeNewswire March 18, 2020

ASLAN Pharmaceuticals to Present at 9th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 24, 2020

ASLAN Pharmaceuticals Announces Closing of US$15 Million Public Offering of American Depositary Shares, Including Full Exercise of Underwriter's Option to Purchase Additional ADSs

GlobeNewswire December 5, 2019